The company anticipates full operational capacity across all assets for the first time in over a decade. Century Aluminum expects adjusted EBITDA of $325M to $345M for Q3 2026, reflecting the completion of two major restarts. The company stated all assets should operate at
Sempra targets over 60% of its 2030 rate base in Texas as part of long-term earnings growth strategy. Sempra (SRE) outlined a 7%-9% long-term adjusted EPS growth target during its Q2 2026 earnings call, citing strong execution and double-digit year-to-date gains. The compa
Perdoceo Education raises full-year earnings outlook and increases dividend after strong first-half performance. Perdoceo Education Corporation raised its quarterly dividend to $0.17 per share and projected 2026 adjusted earnings per share of $3.10 to $3.16. The guidance r
Company reports accelerating momentum in Q2 2026, exceeding prior outlook across all key metrics. Airbnb projected at least mid-teens revenue growth for 2026, signaling sustained expansion following strong first-half performance. The company guided Q3 revenue between $4.69
The company reaffirmed its $2.65B-$2.85B capital expenditure plan while reporting $467 million in adjusted free cash flow for Q2 2026. SM Energy projected second-half 2026 production of 435,000-440,000 barrels of oil equivalent per day, maintaining its earlier guidance. Th
Earnings Call Insights: Alarm.com (ALRM) Q2 2026 Management View - CEO Stephen Trundle said, "We're pleased to report second quarter results that exceeded our expectations," and highlighted SaaS and license revenue of $188.8 million ("up 11% year-over-year") and adjusted EBITDA...</strong
The diagnostics firm forecasts 31% revenue growth excluding true-ups, driven by record test volumes and oncology momentum. Natera set a 2026 revenue outlook of $2.85 billion to $2.91 billion, reflecting 31% growth excluding true-ups. The company processed 1.04 million test
Viatris reports Q2 2026 revenue of $3.8 billion and raises full-year outlook on strong meloxicam performance. Viatris raised its 2026 financial outlook after reporting Q2 2026 revenue of $3.8 billion, adjusted EBITDA of $1.2 billion, and adjusted EPS of $0.69. The company
TRVI expands global trial sites to over 200 as it advances Phase III studies for non-IPF-ILD chronic cough treatment. Trevi Therapeutics plans to align with the FDA in the second half of 2026 for its non-IPF-ILD chronic cough treatment, following the initiation of two Phas
The commercial real estate lender anticipates $12M-$16M in Q3 charges as government-sponsored enterprise reviews conclude. Walker & Dunlop expects $12M-$16M in credit-related charges for Q3 2026 as reviews by government-sponsored enterprises near completion. The charges st
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.